Healthcare institutions as 'hot zones': Emerging and re-emerging pathogens

Current Opinion in Infectious Diseases

Volumn 10, Issue 4, 1997, Pages 310-318

  Henderson, David K ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BLOODBORNE BACTERIUM; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; HOSPITAL; HOSPITAL INFECTION; HUMAN; INFECTION; INFECTION PREVENTION; NONHUMAN; OCCUPATIONAL DISEASE; OCCUPATIONAL HAZARD; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TUBERCULOSIS;

EID: 0030855748     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199708000-00012     Document Type: Review

References (129)

1. Berkelman RL, Pinner RW, Hughes JM: Addressing emerging microbial threats in the United States. JAMA 1996, 275:315-317.
2. Hughes JM, La Montagne JR: Emerging infectious diseases. J Infect Dis 1994, 170:263-264.
3. Hughes JM, Tenover FC: Approaches to limiting emergence of antimicrobial resistance in bacteria in human populations. Clin Infect Dis 1997, 24 (Suppl 1):S131-135.
4. Osterholm MT: Emerging infectious diseases. A real public health crisis? Postgrad Med 1996, 100:15-16, 21, 25-26.
5. Ostroff SM: Emerging infectious diseases in the institutional setting: another hot zone. Infect Control Hosp Epidemiol 1996, 17:484-489.
6. Fidler DP: Globalization, international law, and emerging infectious diseases. Emerg Infect Dis 1996, 2:77-84.
7. Farmer P: Social inequalities and emerging infectious diseases. Emerg Infect Dis 1996, 2:259-269.
8. Gellert GA: Preparing for emerging infections. Nature 1994, 370:409-410.
9. LeDuc JW, Tikhomirov E: Global surveillance for recognition and response to emerging diseases. Ann NY Acad Sci 1994, 740:341-345.
10. LeDuc JW: World Health Organization strategy for emerging infectious diseases. JAMA 1996, 275:318-320. A short paper underscoring the global nature of the problem of increasing antimicrobial resistance. The manuscript details the various approaches that the WHO is taking to address this complex problem.
11. Pinner RW: Addressing the challenges of emerging infectious diseases. Am J Med Sci 1996, 311:3-8.
12. Sieradzki K, Tomasz A: A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus. FEMS Microbiol Lett 1996, 142:161-166.
13. Noble WC, Virani Z, Cree R: Cotransfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992, 93:195-198.
14. Edmond MB, Wenzel RP, Pasculle AW: Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 1996, 124:329-334. The authors address possible strategies for managing patients infected and colonized with vancomycin-resistant S. aureus isolates. Although this is a 'theorectical' problem, in that no such clinical isolates have as yet been detected, this paper places the issue in appropriate perspective and demonstrates the magnitude of the problem that will be presented by these isolates if and when they are clinically identified.
15. Ayliffe GA: The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1997, 24(Suppl 1):S74-S79.
16. Boyce JM, Jackson MM, Pugliese G, Batt MD, Fleming D, Garner JS, Hartstein AI, Kauffman CA, Simmons M, Weinstein R, Williams CO, and The AHA Technical Panel on Infections Within Hospitals: Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. The AHA Technical Panel on Infections Within Hospitals. Infect Control Hosp Epidemiol 1994, 15:105-115.
17. Boyce JM: Methicillin-resistant Staphylococcus aureus: a continuing infection control challenge. Eur J Clin Microbiol Infect Dis 1994, 13:45-49.
18. Boyce JM: Strategies for controlling methicillin-resistant Staphylococcus aureus in hospitals. J Chemother 1995, 7 (Suppl 3):S81-85.
19. Boyce JM: Practical management of patients infected with resistant organisms: an infection control perspective. Adv Exp Med Biol 1995, 390:177-186.
20. Jernigan JA, Clemence MA, Stott GA, et al.: Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect Control Hosp Epidemiol 1995, 16:686-696.
21. Jernigan JA, Titus MG, Groschel DH, Getchell-White S, Farr BM: Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol 1996, 143:496-504 Convincing evidence that the use of contact isolation in an MRSA epidemic was useful in limiting the nosocomial transmission of this organism is provided. The rate of transmission of MRSA from patients who were managed on contact isolation was significantly lower than the rate for patients who were not placed on isolation. in this study, the risk of nosocomial transmission of MRSA was reduced 16-fold by contact isolation during the outbreak. The results of this study, conducted in a neonatal intensive care unit, are consonant with the results of previous focused studies that demonstrated that contact isolation was effective in limiting the epidemic spread of MRSA.
22. Peters G, Becker K: Epidemiology, control and treatment of methicillin-resistant Staphylococcus aureus. Drugs 1996, 52(Suppl 2):50-54.
23. Segal-Maurer S, Urban C, Rahal JJ Jr.: Current perspectives on multidrug-resistant bacteria. Epidemiology and control. Infect Dis Clin North Am 1996, 10:939-957.
24. Wenzel RP: Healthcare workers and the incidence of nosocomial infection: can treatment of one influence the other? A brief review. J Chemother 1994, 6(Suppl 4):S33-37; discussion 39-40.
25. Boyce JM: Treatment and control of colonization in the prevention of nosocomial infections. Infect Control Hosp Epidemiol 1996, 17:256-261.
26. Boyce JM: Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution. Infect Control Hosp Epidemiol 1996, 17:775-779.
27. Perdreau-Remington F, Stefanik D, Peters G, Ludwig C, Rutt J, Wenzel R, Pulverer G: A four-year prospective study on microbial ecology of explanted prosthetic hips in 52 patients with 'aseptic' prosthetic joint loosening. Eur J Clin Microbiol Infect Dis 1996, 15:160-165. The authors evaluated the microbiological aspects of 52 consecutive patients undergoing surgical revision for presumably 'aseptic' joint loosening. More than 75% of the patients had positive cultures, and as one might predict, CNS were the predominant isolates. This manuscript provides yet another example of the fact that CNS isolates have become primary pathogens in infections of all types of medical prostheses.
28. Lyytikainen O, Vaara M, Jarviluoma E, Rosenqvist K, Tiittanen L, Valtonen V: Increased resistance among Staphylococcus epidermidis isolates in a large teaching hospital over a 12-year period. Eur J Clin Microbiol Infect Dis 1996, 15:133-138. This is a retrospective review of the antimicrobial susceptibility of clinically significant blood isolates of Staphylococcus epidermidis at a tertiary care teaching hospital in Helsinki, Finland. The data are remarkable in that resistance to methicillin increased from 28 to 77% in the years from 1983-1994. These data are strikingly similar to data from the US Centers for Disease Control and Prevention's National Nosocomial Infections Study [129]. The rate of resistance among these clinically significant isolates nearly tripled in the years studied.
29. Huebner J, Pier GB, Maslow JN, Muller E, Shiro H, Parent M, Kropec A, Arbeit RD, Goldmann DA: Endemic nosocomial transmission of Staphylococcus epidermidis bacteremia isolates in a neonatal intensive care unit over 10 years. J Infect Dis 1994, 169:526-531.
30. Nesin M, Projan SJ, Kreiswirth B, Bolt Y, Novick RP: Molecular epidemiology of Staphylococcus epidermidis blood isolates from neonatal intensive care unit patients. J Hosp Infect 1995, 31:111-121.
31. Perdreau-Remington F, Stefanik D, Peters G, Ruckdeschel G, Haas F, Wenzel R, Pulverer G: Methicillin-resistant Staphylococcus haemolyticus on the hands of health care workers: a route of transmission or a source? J Hosp Infect 1995, 31:195-205.
32. Lyytikainen O, Saxen H, Ryhanen R, Vaara M, Vuopio-Varkila J: Persistence of a multiresistant clone of Staphylococcus epidermidis in a neonatal intensive-care unit for a four-year period. Clin Infect Dis 1995, 20:24-29.
33. Bonten MJ, Hayden MK, Nathan C, van Voorhis J, Matushek M, Slaughter S, Rice T, Weinstein RA: Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet 1996, 348:1615-1619.
34. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, Romulo RL, Fortna S, Medeiros AA: Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994, 32:1148-1153.
35. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995, 20:1126-1133.
36. Quale J, Landman D, Atwood E, Kreiswirth B, Willey BM, Ditore V, Zaman M, Patel K, Saurina G, Huang W, Oydna E, Burney S: Experience with a hospital-wide outbreak of vancomycin-resistant enterococci. Am J Infect Control 1996, 24:372-379.
37. Shay DK, Moloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, Bland LA, Jarvis WR: Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995, 172:993-1000.
38. Suppola JP, Volin L, Valtonen VV, Vaara M: Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis 1996, 23:694-697.
39. Stroud L, Edwards J, Danzing L, Culver D, Gaynes R: Risk factors for mortality associated with enterococcal bloodstream infections. Infect Control Hosp Epidemiol 1996, 17:576-580.
40. Arthur M, Reynolds P, Courvalin P: Glycopeptide resistance in enterococci. Trends Microbiol 1996, 4:401-407.
41. Boyce JM, Mermel LA, Zervos MJ, Rice LB, Potter-Bynoe G, Giorgio C, Medeiros JAA: Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1995, 16:634-637.
42. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP: Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996, 23:1234-1239.
43. Leclercq R: Enterococci acquire new kinds of resistance. Clin Infect Dis 1997, 24(Suppl 1):S80-S84.
44. Montecalvo MA, Shay DK, Patel P, Tacsa L, Maloney SA, Jarvis WR, Wormser GP: Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996, 156:1458-1462.
45. Palmer SM, Rybak MJ: Vancomycin-resistant enterococci. Pharmacotherapy 1996, 16:819-829.
46. Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, Kusne S: Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996, 22:663-670.
47. Mobarakai N, Quale JM, Landman D: Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother 1994, 38:385-387.
48. Mobarakai N, Landman D, Quale JM: In-vitro activity of trospectomycin, a new aminocyclitol antibiotic, against multidrug-resistant Enterococcus faecium. J Antimicrob Chemother 1994, 33:319-321.
49. Zervos M: Vancomycin-resistant Enterococcus faecium infections in the ICU and quinupristin/dalfopristin. New Horiz 1996, 4:385-392.
50. Landman D, Quale JM, Oydna E, Willey B, Ditore V, Zaman M, Patel K, Saurina G, Huang W: Comparison of five selective media for identifying fecal carriage of vancomycin-resistant enterococci. J Clin Microbiol 1996, 34:751-752.
51. Mayhall CG: Prevention and control of vancomycin resistance in gram-positive coccal microorganisms: fire prevention and fire fighting [Editorial]. Infect Control Hosp Epidemiol 1996, 17:353-355.
52. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K: Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996, 23:1020-1025.
53. Shay DK, Goldmann DA, Jarvis WR: Reducing the spread of antimicrobial-resistant microorganisms. Control of vancomycin-resistant enterococci. Pediatr Clin North Am 1995, 42:703-716.
54. Jarvis WR: Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: the complexity of the problem. Infect Control Hosp Epidemiol 1996, 17:490-495. A thoughtful editorial summarizing the complexity of the problem of antimicrobial resistance, emphasizing that a 'quick-fix' is extremely unlikely, and also emphasizing that individual institutions will need to tailor their strategies to manage this complex problem specifically to meet the needs of their own institutions. No 'one-size-fits-all' set of management recommendations exist.
55. Jarvis WR: Handwashing - the Semmelweis lesson forgotten? Lancet 1994, 344:1311-1312.
56. Stead WW, Eisenach KD, Cave MD, Beggs ML, Templeton GL, Theon CO, Bates JH: When did Mycobacterium tuberculosis infection first occur in the New World? An important question with public health implications. Am J Respir Crit Care Med 1995, 151:1267-1268.
57. Stead WW, Lofgren JP, Senner JW: Invited commentary: relative susceptibility of black Americans to tuberculosis. Am J Epidemiol 1994, 139:531-532; discussion 533-534.
58. Templeton GL, Illing LA, Young L, Cave D, Stead WW, Bates JH: The risk for transmission of Mycobacterium tuberculosis at the bedside and during autopsy. Ann Intern Med 1995, 122:922-925.
59. Zaza S, Blumberg HM, Beck-Sague C, Haas WH, Woodley CL, Pineda M, Parrish C, Crawford JT, McGowan JE Jr, Jarvis WR: Nosocomial transmission of Mycobacterium tuberculosis: role of health care workers in outbreak propagation. J Infect Dis 1995, 172:1542-1549.
60. Zaza S, Beck-Sague CM, Jarvis WR: Tracing patients exposed to health care workers with tuberculosis. Public Health Rep 1997, 112:153-157.
61. Adal KA, Anglim AM, Palumbo CL, Titus MG, Coyner BJ, Farr BM: The use of high-efficiency particulate air-filter respirators to protect hospital workers from tuberculosis. A cost-effectiveness analysis. N Engl J Med 1994, 331:169-173.
62. Jarvis WR, Bolyard EA, Bozzi CJ, Burwen DR, Dooley SW, Martin LS, Mullan RJ, Simone PM: Respirators, recommendations, and regulations: the controversy surrounding protection of health care workers from tuberculosis. Ann Intern Med 1995, 122:142-146.
63. Jereb JA, Klevens RM, Privert TD, Smith PJ, Crawford JT, Sharp VL, Davis BJ, Jarvis WR, Dooley SW: Tuberculosis in health care workers at a hospital with an outbreak of multidrug-resistant Mycobacterium tuberculosis. Arch Intern Med 1995, 155:854-859.
64. Maloney SA, Pearson ML, Gordon MT, Del Castillo R, Boyle JF, Jarvis WR: Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers. Ann Intern Med 1995, 122:90-95.
65. Stead WW, Yeung C, Harnett C: Probable role of ultraviolet irradiation in preventing transmission of tuberculosis: a case study. Infect Control Hosp Epidemiol 1996, 17:11-13.
66. Stroud LA, Tokars JI, Grieco MH, Crawford JT, Culver DH, Edlin BR, Sordillo EM, Woodley CL, Gilligan ME, Schneider N, Williams J, Jarvis WR: Evaluation of infection control measures in preventing the nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in a New York City hospital. Infect Control Hosp Epidemiol 1995, 16:141-147.
67. Wenger PN, Otten J, Breeden A, Orfas D, Beck-Sague CM, Jarvis WR: Control of nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet 1995, 345:235-240.
68. Flaherty JP, Weinstein RA: Nosocomial infection caused by antibiotic-resistant organisms in the intensive-care unit. Infect Control Hosp Epidemiol 1996, 17:236-248.
69. Gold HS, Moellering RC Jr.: Antimicrobial-drug resistance. N Engl J Med 1996, 335:1445-1453. A 'state-of-the-art' summary of the problem of increasing antimicrobial resistance.
70. Jack DB: Drug-resistant bacteria: responding to the infectious disease crisis. Mol Med Today 1996, 2:499-502.
71. Mao CA, Siegler EL, Abrutyn E: Antimicrobial resistance patterns in long term geriatric care. Implications for drug therapy. Drugs Aging 1996, 8:162-170.
72. Miller PF, Sulavik MC: Overlaps and parallels in the regulation of intrinsic multiple-antibiotic resistance in Escherichia coli. Mol Microbiol 1996, 21:441-448.
73. Lucet JC, Chevret S, Decre D, Vanjak D, Macrez A, Bedos JP, Wolff M, Regnier B: Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996, 22:430-436.
74. Rowe B, Ward LR, Threlfall EJ: Multidrug-resistant Salmonella ryphi: a worldwide epidemic. Clin Infect Dis 1997, 24(Suppl 1):S106-109.
75. Garrett DO, Jarvis WR: The expanding role of healthcare epidemiology - home and long-term care. Infect Control Hosp Epidemiol 1996, 17:714-717.
76. Tomasz A: Antibiotic resistance in Steptococcus pneumoniae. Clin Infect Dis 1997, 24 (Suppl 1):S85-S88.
77. Rodriguez-Barradas MC, Tharapel RA, Groover JE, Giron KP, Lacke CE, ouston ED, Hamill RJ, Steinhoff MC, Musher DM: Colonization by Streptococcus pneumoniae among human immunodeficiency virus-infected adults: prevalence of antibiotic resistance, impact of immunization, and characterization by polymerase chain reaction with BOX primers of isolates from persistent S. pneumoniae carriers. J Infect Dis 1997, 175:590-597.
78. Cetron MS, Jernigan DB, Breiman RF: Action plan for drug-resistant Streptococcus pneumoniae. The DRSP Working Group. Emerg Infect Dis 1995, 1:64-65.
79. Jernigan DB, Cetron MS, Breiman RF: Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group. JAMA 1996, 275:206-209.
80. Lind I: Antimicrobial resistance in Neisseria gonorrhoeae. Clin Infect Dis 1997, 24(Suppl 1):S93-S97.
81. Oppenheim BA: Antibiotic resistance in Neisseria meningitidis. Clin Infect Dis 1997, 24 (Suppl 1):S98-S101.
82. Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS, Lewis WF, Notari EP, Petersen LR: Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995, 333:1721-1725.
83. Bell DM, Shapiro CN, Ciesielski CA, Chamberland ME: Preventing bloodborne pathogen transmission from health-care workers to patients. The CDC perspective. Surg Clin North Am 1995, 75:1189-1203.
84. Gerberding JL: The infected health care provider. N Engl J Med 1996, 334:594-595.
85. Lot FL, and the National Public Health Network of France (Reseau National de Sante Publique): HIV transmission from an orthopedic surgeon to a patient in France. Presented at the Seventh Annual Meeting of the Society for Hospital Epidemiology of America, St. Louis, Mo. April 27, 1997.
86. Mclvor C, Morton J, Bryant A, Cooksley WG, Durrant S, Walker N: Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med 1994, 121:274-275.
87. Harpaz R, Von Seidlein L, Averhoff FM, Tormey MP, Sinha SD, Kotsopoulou K, Lambert SB, Robertson BH, Cherry JD, Shapiro CN, Centre Incident Investigation Teams and others: Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med 1996, 334:549-554.
88. Public Health Laboratory Service Communicable Disease Surveillance Centre Incident Investigation Teams and others: Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. N Engl J Med 1997, 336:178-184. This group describes the transmission of hepatitis B from four surgeons to their patients during surgery, despite the fact that the surgeons did not have detectable levels of hepatitis B 'e' antigen. Transmission has generally been associated with healthcare providers who are 'e' antigen positive. These four surgeons were all infected with a so-called 'pre-core mutant' of hepatitis B, which does not make hepatitis B 'e' antigen. The impact of these cases on the overall management of healthcare workers who are infected with HBV is unclear.
89. Esteban JI, Gomez J, Martell M, Cabot B, Quer J, Camps J, Gonzalez A, Otero T, Moya A, Esteban JR, Guardia J: Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996, 334:555-560.
90. Gerberding JL, Littell C, Tarkington A, Brown A, Schecter WP: Risk of exposure of surgical personnel to patients' blood during surgery at San Francisco General Hospital. N Engl J Med 1990, 322:1788-1793.
91. Public Health Laboratory Service: Hepatitis C Transmission from health care worker to patient. PHLS Communicable Dis Rep 1995, 5:121.
92. Stead WW: Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. Ann Intern Med 1995, 122:906-912.
93. Centers for Disease Control and Prevention: Guidelines for preventing the transmission of tuberculosis in health-care facilities, 1994. MMWR Morb Mortal Wkly Rep 1994, 43:1-132.
94. Hernandez MF, Bruguera M, Puyuelo T, Barrera JM, Sanchez TJ, Rodies J: Risk of needle-stick injuries in the transmission of hepatitis C virus in hospital personnel. J Hepatol 1992, 16:56-58.
95. Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, Nishioka K, Purcell RH, Alter H: Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991, 115:367-369.
96. Lanphear BP, Linnemann CC, Cannon CG, DeRonde MN, Pendy L, Kerley LM: Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994, 15:745-750.
97. Mitsui T, Iwano K, Masuko K, Yamazaki C, Okamoto H, Tsuda F, Tanaka T, Mishiro S: Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992, 16:1109-1114.
98. Sodeyama T, Kiyosawa K, Urushihara A, Matsumoto A, Tanaka E, Furuta S, Akahane Y: Detection of hepatitis C virus markers and hepatitis C genomic-RNA after needlestick accidents. Arch Intern Med 1993, 153:1565-1572.
99. Cooksley WG, Butterworth LA: Hepatitis C virus infection in health care workers referred to a heptatitis clinic. Med J Aust 1996, 164:656-658.
100. Davis GL: Hepatitis C virus infection among health care workers. JAMA 1996, 275:1474.
101. Gerberding JL: Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalo-virus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis 1994, 170:1410-1417.
102. Stroffolini T, Marzolini A, Palumbo F, Novaco F, Moiraghi A, Balocchini E, Bernacchia R, Corona R, Mele A: Incidence of non-A, non-B and HCV positive hepatitis in healthcare workers in Italy. J Hosp Infect 1996, 33:131-137.
103. Thomas DL, Gruninger SE, Siew C, Joy ED, Quinn TC: Occupational risk of hepatitis C infections among general dentists and oral surgeons in North America. Am J Med 1996, 100:41-45.
104. Robert LM, Bell DM: HIV transmission in the health-care setting. Risks to health-care workers and patients. Infect Dis Clin North Am 1994, 8:319-329.
105. Chamberland ME, Ciesielski CA, Howard RJ, Fry DE, Bell DM: Occupational risk of infection with human immunodeficiency virus. Surg Clin North Am 1995, 75:1057-1070.
106. Gerberding JL, Quebbeman EJ, Rhodes RS: Hand protection. Surg Clin North Am 1995, 75:1133-1139.
107. Gerberding JL, Lewis FR Jr, Schecter WP: Are universal precautions realistic? Surg Clin North Am 1995, 75:1091-1104.
108. Gerberding JL: Prevention of human immunodeficiency virus infection among hospital personnel. Curr Clin Top Infect Dis 1994, 14:220-227.
109. Chamberland ME, Petersen LR, Munn VP, White C, Johnson ES, Busch MP, Grindon AJ, Kamel H, Ness PM, Shafer AW, Zeger G: Human immunodeficiency virus infection among health care workers who donate blood. Ann Intern Med 1994, 121:269-273.
110. Orenstein R, Reynolds L, Karabaic M, Lamb A, Markowitz SM, Wong ES: Do protective devices prevent needlestick injuries among health care workers? Am J Infect Control 1995, 23:344-351.
111. Tokars JI, Culver DH, Mendelson MH, Sloan EP, Farber BF, Fligner DJ, Chamberland ME, Marcus R, McKibben PS, Bell DM: Skin and mucous membrane contacts with blood during surgical procedures: risk and prevention. Infect Control Hosp Epidemiol 1995, 16:703-711.
112. Gerberding JL: Management of occupational exposures to bloodborne viruses. New Engl J Med 1995, 332:444-451.
113. Centers for Disease Control and Prevention: Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep 1995, 44:929-933.
114. Henderson DK: Postexposure prophylaxis for occupational exposures to hepatitis B, hepatitis C, and human immunodeficiency virus. Surg Clin North Am 1995, 75:1175-1187.
115. Henderson D: Prophylaxis for bloodborne infections. 31st Annual Meeting. New Orleans, Louisiana: Infectious Diseases Society of America; 1993:9.
116. Henderson DK: Human immunodeficiency virus in the health-care setting. In Principles and practice of infectious diseases 4th ed. Edited by Mandell G, Dolin R, Bennett J. New York: Churchill-Livingstone; 1994:2632-2656.
117. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, Benveniste E, Black R: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995, 270:1197-1199.
118. Connor E, Sperling R, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
119. Centers for Disease Control and Prevention: Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 1996, 45:468-480 These provisional US Public Health Service recommendations are the first to endorse the use of post-exposure chemoprophylaxis for healthcare workers who have sustained occupational exposures to HIV. The recommendations are stratified by exposure type. For the most severe exposures, the guidelines recommend the use of three drugs - zidovudine, lamivudine, and indinavir.
120. Connor E, Sperling R, Gelber R, Kiseley P, Scott G, O'Sullivan AM, Van Dyke R, Bey M, Shearer W, Jacobsen RL et al.: Transfusion-transmitted human T-cell lymphotropic virus type I infection in Taiwan: a true risk and occasional coinfection with hepatitis C virus shown in a prospective study. Blood 1994, 84:934-940.
121. Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R, Shih JW, Kim JP: The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997, 336:747-754. Alter et al. provide the first information about the clinical relevance of the newest member of the hepatitis alphabet, hepatitis G. Using banked samples from an ongoing study of post-transfusion hepatitis. They demonstrated that hepatitis G virus infection was associated with only a mild hepatitis syndrome; all were anicteric with only mild elevations of alanine aminotransferase levels. In this cohort, 35 infections were identified among the 357 transfusion recipients; only three had hepatitis with hepatitis G as the sole viral marker. The authors noted that most of the hepatitis G virus infections were not associated with hepatitis and concluded that, at least thus far, no clear casual relation between hepatitis G virus and hepatitis could be established.
122. Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE, Krawc'ynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S: Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996, 271:505-508.
123. Nakatsuji Y, Shih JW, Tanaka E, Kiyosawa K, Wages J Jr, Kim JP, Alter HJ: Prevalence and disease association of hepatitis G virus infection in Japan. J Viral Hepat 1996, 3:307-316.
124. Alter HJ: The cloning and clinical implications of HGV and HGBV-C. N Engl J Med 1996, 334:1536-1537.
125. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, Schlosser J, Martone WJ: Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996, 275:234-240. The output of a group of experts convened to develop strategies to manage the problem of antimicrobial resistance is discribed. The group settled on 10 strategic goals and related process and outcome measures, five related to strategies designed to optimise antimicrobial use and five to detect, report, and prevent transmission of antimicrobial resistant organisms. Among the most important points made by this team of experts is the recommendation that the healthcare institution's administration leadership exhibits institutional 'ownership' of the issue.
126. Goldmann DA, Huskins WC: Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide. Clin Infect Dis 1997, 24 (Suppl 1):S139-S145.
127. O'Brien TF: The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. Clin Infect Dis 1997, 24 (Suppl 1):S2-S8.
128. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistance Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 1997, 40:in press.
129. Schaberg DR, Culver DH, Gaynes RP: Major trends in the microbial etiology of nosocomial infection. Amer J Med 1991, 91 (Suppl 3B):72S-75S.